- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01449552
Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After TKA: A Prospective RCT
November 4, 2011 updated by: Keerati Charoencholvanich, Mahidol University
Temporary Clamping of Drains Combined With Tranexamic Acid Reduce Blood Loss After Total Knee Arthroplasty: A Prospective Randomized Controlled Trial.
Total knee arthroplasty (TKA) may be associated with significant blood loss, and transfusion carries substantial risk of immunologic reaction and disease transmission.
Several methods reportedly reduce postoperative blood loss and avoid homologous blood transfusion with traditional TKA approaches.
Drain clamping was one of the widely used method and tranexamic acid administration was the recently adjuvant method to reduce blood loss in TKA.
However, there were several regimens in either drain clamping or tranexamic acid administration reported in previous studies.
Our objective was to compare the efficacy of our drain clamping protocol and/or tranexamic acid regimen for reducing blood loss and transfusion in TKA.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
240
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patients younger than 85 years with knee osteoarthritis
Exclusion Criteria:
- The patient diagnosed secondary osteoarthritis (eg, rheumatoid arthritis, posttraumatic arthritis, gouty arthritis, postseptic arthritis)
- High-risk medical comorbid patient
- The patient who was planed for simultaneous bilateral TKAs
- The patient who had history of thromboembolic disease or bleeding disorder
- The patient who was receiving anticoagulant drug treatment
- The patient who had allergy to tranexamic acid
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group A
No clamp and placebo
|
The drain was not clamped.
The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
|
|
Experimental: Group B
Tranexamic acid
|
the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
|
|
Experimental: Group C
Drain clamping
|
the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours.
The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
|
|
Experimental: Group D
Drain clamping and tranexamic acid
|
the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours.
the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Postoperative blood loss
Time Frame: 48 hours after operation
|
48 hours after operation
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of blood transfusion
Time Frame: 5 days
|
5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Keerati Charoencholvanich, MD, Mahidol University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
November 1, 2008
Study Registration Dates
First Submitted
October 5, 2011
First Submitted That Met QC Criteria
October 7, 2011
First Posted (Estimate)
October 10, 2011
Study Record Updates
Last Update Posted (Estimate)
November 6, 2011
Last Update Submitted That Met QC Criteria
November 4, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Si463/2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.